anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Infants hospitalized for bronchiolitis are at high risk for developing recurrent wheeze in childhood. The role of airway lipids in the link between these two conditions remains unclear. This study aimed to identify the association between airway lipids in infants hospitalized for bronchiolitis and the development of recurrent wheeze, with a focus on immunoglobulin E (IgE) sensitization.
METHODS: In a multicenter prospective cohort study of 919 infants (age <1 year) hospitalized for bronchiolitis, we performed lipidomic profiling of nasopharyngeal airway specimens collected at hospitalization. We first identified lipid modules composed of highly correlated lipids by performing weighted correlation network analysis. We then examined the longitudinal association of those lipid modules with the rate of recurrent wheeze by age 3 years after discharge from hospitalization for bronchiolitis. We also examined the associations of lipid modules with IgE non-sensitized (i.e., neither sensitized at admission nor at age 3 years) and IgE-sensitized (i.e., sensitized at admission and/or at age 3 years) recurrent wheeze by age 3 years, respectively.
RESULTS: Our analysis identified 15 distinct lipid modules in the nasopharyngeal airway lipidome data. Overall, lipid modules composed of triacylglycerols (hazard ratio [HR] 1.78, 95% confidence interval [CI] 1.26-2.51, FDR < 0.01) and sphingolipids (HR 1.74, 95% CI 1.25-2.44, FDR <0.01) had the strongest associations with recurrent wheeze development. Stratification by IgE sensitization revealed differential associations. For example, the module composed of triacylglycerols was significantly associated with IgE non-sensitized recurrent wheeze, whereas the module composed of sphingolipids was significantly associated with IgE-sensitized recurrent wheeze (both FDR <0.05).
CONCLUSION: Distinct nasopharyngeal airway lipid modules are associated with recurrent wheeze development following severe bronchiolitis, with different patterns based on IgE sensitization status.
The invention particularly discloses a traditional Chinese medicine composition, a preparation method thereof and application thereof in preparing medicines with fatty liver prevention and treatment effects. The traditional Chinese medicine composition comprises the following raw material components: radix et rhizoma Rhei preparata, herba Gynostemmatis, semen Sinapis Albae, and Mirabilitum. In addition, the composition also comprises sedum sarmentosum. The traditional Chinese medicine composition prepared from four traditional Chinese medicines of prepared rheum officinale, gynostemma pentaphylla, semen brassicae and mirabilite has excellent blood lipid reducing effect and fatty liver preventing and treating effect. In addition, sedum sarmentosum is further added into four medicinal materials of rheum officinale, gynostemma pentaphylla, semen brassicae and mirabilite, so that the blood lipid reducing effect and fatty liver preventing and treating effect of the traditional Chinese medicine composition prepared by the sedum sarmentosum can be remarkably improved. Compared with the traditional Chinese medicine for treating fatty liver in the prior art, the traditional Chinese medicine for treating fatty liver has the advantages of greatly reduced composition, no valuable medicine or toxic medicine, safety, reliability, low technical risk, wide market demand and obvious economic and social benefits.
A Papaver from rhoeas' cell and tissue stain is formulated incorporating a new one bioflavonoid which specifically stains the nucleus for microscopic evaluation in histopathology, microbiology and cytology. It appears to be an alternative to hematoxylin for routine usage. Biochemical name of this compound; tetrahydro-3,4,5-trihydroxy-6-methyl-2H-pyran-2-yloksil)methyl)2H-pyran-2,3,4,5-tetraol)-4- methoxyphenyl) -7-methoxy-4H-chromen-4-one NMR analysis shows the biochemical structure of molecule is a bioflavonoid, (figure 4,5) Molecule within Papaver rhoeas along with the synergistic and other molecules penetrates the biologic and nonbiologic samples. Combining with the other synergistic mechanisms the stain formula is prepared. The amount and type of Mordant and pH are the parameters that affect the quality and timing of the staining results. Papaver rhoeas formula is prepared especially for the examination of tissues for the diagnostics in laboratories and hospitals and is intended to be used routinely. Worldwide the millions of biologic samples are reviewed for surgical preparations and biological are samples stained for diagnosis. (The hematoxylin tissue stain is used in the routine, is produced from the trees called Hematoxylin campechianum (logwood)which is a member of the world's rainforests. Every year 3000 Logwood tree as well as the fields are demolished to produce, approximately 1200 tons of powder and 70,000 tons of liquid hematoxylin dye. ($ 15 billion / year). Papaver from rhoeas' provides effective and specific staining resulting in highlighting the nucleus. Besides the obvious economic contribution Papaver rhoeas widely grows and can be easily harvested and produced. The Papaver rhoeas Formula has also an ecological impact on Earth that will allow to be an important and valuable industrial products.
<P>PROBLEM TO BE SOLVED: To provide a medicine dosage information management system by which a patient himself/herself can obtain and confirm medicine information, and whether or not the patient takes a medicine at the time determined by a doctor can be confirmed.  <P>SOLUTION: The medicine dosage information management system is composed of: a medicine package to which a non-contact IC tag is attached; and a radio communication terminal for the patient and a radio communication terminal for the doctor. The non-contact IC tag is provided with a storage part storing the ID information and medicine explanation information of the medicine and a communication part. The radio communication terminal for the patient is provided with a communication part for receiving the ID information and the medicine explanation information from the non-contact IC tag and transmitting the ID information to the radio communication terminal for the doctor, a timing part, an input part, a display part, and a storage part for storing the received ID information as the information of the medicine that is already taken. The radio communication terminal for the doctor is provided with a storage part storing medication schedule information, a means for storing the received ID information in the storage part as medicine dosage history information, a means for collating the medication schedule information and the medicine dosage history information, and a display part for displaying a collated result.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Fractures of bones are commonly encountered in traumatic injuries, and distinguishing between antemortem (AM) and postmortem (PM) bone fractures is crucial for estimating the time since injury and has important medicolegal implications. Correct differentiation enables understanding the dynamics of the injury and, in some cases, the cause of death. The present study aims to evaluate the gross morphological and histopathological characteristics of bony fracture surfaces to determine whether they occurred before or after an individual's death.Fifty-seven sets of bone samples, including both antemortem and artificially created postmortem fractures, were collected from cadavers during medicolegal autopsies, meeting the inclusion criteria. Gross morphological and histopathological features were examined after staining the bony fracture edges with hematoxylin and eosin stain. The study revealed distinct morphological characteristics at fracture surfaces for both antemortem and artificially created postmortem fractures. In addition, signs of vital reaction were observed exclusively in antemortem fracture cases.In conclusion, the findings emphasize the importance of meticulous morphological and histopathological examination of bony fracture surfaces to differentiate between antemortem fractures and artificially created postmortem artifacts. This differentiation holds significant value in forensic investigations and medicolegal cases.
Pre-surgery scans, surgical resection and post-surgery pathological assessment. All patients will receive standard of care imaging and blood tests. If suitable, non-standard of care abdominal MRI imaging will be done. 16-24 hours prior to surgery, patients will be administered a single dose of 0.5 g/m\^2 pimonidazole (HydroxyProbe).
The toxic effects of perphenazine are typically mild to moderate with death occurring in cases involving a large overdose. Overdosage of perphenazine primarily involves the extrapyramidal mechanism and produces the same side effects described under ADVERSE REACTIONS, but to a more marked degree. It is usually evidenced by stupor or coma; children may have convulsive seizures. Signs of arousal may not occur for 48 hours. The primary effects of medical concern are cardiac in origin including tachycardia, prolongation of the QRS or QTc intervals, atrioventricular block, torsade de pointes, ventricular dysrhythmia, hypotension or cardiac arrest, which indicate serious poisoning. Deaths by deliberate or accidental overdosage have occurred with this class of drugs.
The invention relates to a traditional Chinese medicine for curing gynecologic chronic pelvic inflammatory disease and a preparation method thereof. Bulk drugs of the traditional Chinese medicine comprise amoorcorn tree bark, angelica, hemlock parsley, white peony root, radix rehmanniae, licorice, dried ginger, ailanthus bark and caladium. In light of the physicochemical properties of the effective constituents in prescribed drugs, the invention adopts orthogonal experiment to optimize the technological parameters thereof, thereby greatly improving the content of the effective constituents therein and ensuring the efficiency of curing gynecologic chronic pelvic inflammatory disease. The preparation method provided is characterized by simple production, high concentration of effective constituents and stable product quality. As no auxiliary material is used in the prescription, auxiliary material without potency is not contained in the effective constituents of the medicine, thus reducing dose to be taken and facilitating oral administration by sufferers; and the medicine does not contain sugar content, and sufferers can take the medicine conveniently without contraindication. Animal experiments prove that the traditional Chinese medicine of the invention has prominent pharmacological actions, such as anti-inflammatory effect, antibacterial effect, the effect of pain and itching relieving, improving microcirculation, improving organism immunity, etc., and the traditional Chinese medicine does not have obvious toxicity and side effect and can be taken for a consecutive long time. The traditional Chinese medicine of the invention has remarkable curative effect on relevant gynecologic inflammations, such as chronic pelvic inflammatory disease with the type of moist heat, accumulation of sthenia-heat, qi stagnation and blood stasis, vaginitis, cervicitis, annexitis and urinary tract infection.
The purpose of this invention is to cool a human body from the inside over a prolonged period of time. This is done by swallowing a cooling unit in order to provide cooling within the gastrointestional tract. The unit consists predominantly of a cooling agent and a protective layer. The protective layer itself allows for comfortable ingestion and disintegration of the protective layer within the gastrointestinal tract causes the cooling power to be released over an extended period of time. his specific invention concerns the internal cooling of a body by swallowing cooling units that can provide internal cooling over a prolonged period of time. The cooling unit consists of a cooling agent (i.e. ice) and a protective layer covering the cooling agent. When the cooling unit is swallowed, there will be little inconvenience of the cold of the cooling agent. The units can provide internal cooling over a prolonged period of time(> 20 minutes) depending on the content of the protective layer.
OBJECTIVE: Systemic lupus erythematosus (SLE) flares are associated with increased damage and decreased health-related quality of life. We hypothesized that there is discordance between physicians' and patients' views of SLE flare. In this study, we aimed to explore patient and physician descriptions of SLE flares.
METHODS: We conducted a qualitative descriptive study using in-depth interviews with a purposeful sample of patients with SLE (who met 1997 American College of Rheumatology or Systemic Lupus International Collaborating Clinics criteria) and practicing rheumatologists. Interviews were audio-recorded, transcribed, and analyzed using applied thematic analysis.
RESULTS: Forty-two patient participants with SLE, representing a range of SLE activity, completed interviews. The majority described flare symptoms as joint pain, fatigue, and skin issues lasting several days. Few included objective signs or laboratory measures, when available, as features of flare. We interviewed 13 rheumatologists from 10 academic and 3 community settings. The majority defined flare as increased or worsening SLE disease activity, with slightly more than half requiring objective findings. Around half of the rheumatologists included fatigue, pain, or other patient-reported symptoms.
CONCLUSION: Patients and physicians described flare differently. Participants with SLE perceived flares as several days of fatigue, pain, and skin issues. Providers defined flares as periods of increased clinical SLE activity. Our findings suggest the current definition of flare may be insufficient to integrate both perceptions. Further study is needed to understand the pathophysiology of patient flares and the best way to incorporate patients' perspectives into clinical assessments.
A 27-gauge needle will be placed via the shaft of the epidural needle inserted at the L2-3/L3-4 inter-space by the investigator. After confirming the CSF, 2,5 mg of bupivacaine with 20 µg of fentanyl will be injected. That will be followed by the placement of a 20-gauge multi-hole catheter into the epidural space which will be connected to the PCA pump with a possibility of injecting 6-10 ml 0,1% bupivacaine with 2 µg of fentanyl/ml every 20 min with no background infusion.
RESP-FIT. The RESP-FIT program is a 6-week respiratory muscle strength training intervention adapted from previous respiratory muscle strength training (RMST) training regimens, consisting of 1) five training days/week using combined inspiratory and expiratory muscle training, consisting of breathing in and out against a combine inspiratory and expiratory muscle strength trainer (IMST/EMST), 2) individualized, progress-based text message training reminders and prompts related to timing and intensification calibration, and 3) use of a Fitbit for remote monitoring of physical activity and hours slept at night. Similar to other muscle strength training programs, exercises are done at regular intervals during the week (5 breaths, 5 times a day, 5 days a week; the participant will receive graphical illustration of RESP-FIT training frequency and intensity achieved, and based on their training regimen, will be prompted and/or reinforced via SMS text messaging). As the use of an accelerometer or remote tracking device alone may affect physical activity, a control group will receive only the Fitbit. This study proposes to assess the feasibility and initial efficacy of RMST by obtaining estimates of variability in fatigue secondary to dyspnea, using a technologically-enhanced RESP-FIT intervention. Our overarching hypothesis is that a training regimen consisting of RMST along with technology-enhanced symptom-tracking will decrease dyspnea, dyspnea-related activity avoidance, and fatigue. Additionally, this application proposes to further develop Smartphone Airway Monitoring System (SAMS) which currently integrates EMA probe questions covering COPD symptoms and preventive care use with the new functions, use in an adult population with COPD, video captured training technique and logging of RMST training sessions. Up to thirty adults with COPD (age over 40) will complete the study and use the SAMS app for 6 weeks in the natural environment. We will evaluate the acceptability, feasibility, adherence, and performance of RESP-FIT + SAMS through quantitative methods to further optimize the app and related study procedures for the next phase of testing (i.e., large scale efficacy RCT).
A new type of restraint device, which is an adjustable protective restraint device (patent number ZL202020155913.1), including upper fixation bracket I, upper fixation bracket II, lower fixation bracket I, lower fixation bracket II and gloves; The plurality of fixed brackets are provided with breathable holes and breathable cotton is placed to increase air permeability and comfort. Place the patient's elbow joint on top of the lower fixation bracket I and II, and then install and connect the upper fixation bracket I and the upper fixation bracket 2 through the upper and lower tightening belts, and adjust their tightness; The upper and lower fixed bracket connections are adjustment module 1 and adjustment module 2, forming a detachable and rotating connection within a certain angle range to adjust the angle of elbow joint movement of the patient; The patient's hand is made by wearing gloves with a grip ball on the palm surface.
HIV incidence is high among MSM in Lima, Peru, and bacterial sexually transmitted diseases (STDs) and HSV-2 are prevalent in both recently and chronically HIV-infected MSM as well as HIV-uninfected MSM. Bisexual HIV-infected MSM could be an important "bridge" transmitting HIV and other STDs to women. Interventions to reduce both HIV and STDs are urgently needed among MSM in Peru. Given these associations and the high prevalence of STDs among MSM in Lima, prevention of HIV infections is dependent partially on innovative methods to control bacterial and viral STDs among high-risk HIV-uninfected MSM. The data from this prevention preparedness study is critical for future HIV prevention and vaccine trials that will be conducted in Peru.

All MSM are counseled and tested for HIV, HSV-2, and syphilis at the screening visit. \[AS PER AMENDMENT 07/23/02: The syphilis test results are provided at screening, whereas the HIV and HSV-2 test results are provided at the enrollment visit.\] High-risk HIV-uninfected MSM in Lima, Peru, are enrolled. Men are interviewed about risk behaviors in the past 6 months. Trained counselors provide risk-reduction counseling according to locally accepted standards. Men are followed at 3-month intervals for 1 year to determine the incidence of and risk factors for prevalent and incident HIV and HSV-2, and to evaluate the effectiveness of retention strategies. In the baseline questionnaire, 2 additional modules address sexual networks and willingness to participate in HIV vaccine or prevention trials, including an acyclovir trial. Study data are collected and entered into a local database.
A system for automating coordinated care management by mapping medical guidelines to clinical workflows and logistical operations may be provided. The system may include a mapping system, a medical guidelines database, a clinical workflow database and a logistical workflow database. The mapping system may receive medical guidelines from the medical guidelines database, generate clinical workflows to be stored in the clinical workflow database, and generate logistical workflows to be stored in the logistical workflow database. The logistical workflows can be generated from clinical workflows or directly from medical guidelines. The system may include a communications system that automatically manages communications between participants in a healthcare system using computer code generated based on the logistical workflows. The system may also monitor patient response and outcome information in order to yield predictive patient engagement efficiencies to address current fragmentation and inefficiencies of care coordination.
PURPOSE: A method for manufacturing a stable pharmaceutical composition containing eperisone or a pharmaceutically acceptable salt thereof is provided to suppress generation of related compounds from eperisone, and to maintain the content of an active ingredient through dry-granulation without a solvent. CONSTITUTION: A method for manufacturing a pharmaceutical composition comprises the steps of: mixing eperisone or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient in a blender without a solvent; and dry-granulating the mixture by compression molding and crush-granulating. Eperisone or the pharmaceutically acceptable salt is eperisone hydrochloride. The pharmaceutical composition contains 10-70 wt% of eperisone or the pharmaceutically acceptable salt. The pharmaceutically acceptable excipient is a combination of a dispersing agent, a disintegrant, and a binder. The dispersing agent is selected from the group consisting of lactose, microcrystalline cellulose, mannitol, and a mixture thereof. [Reference numerals] (AA) Severe condition-1; (BB,GG) Related compound 1; (CC,HH) Example 1; (DD,II) Comparative example 1; (EE,JJ) Comparative example 2; (FF) Severe condition-2
This is a research study to determine whether a medication called D-cycloserine (DCS) in combination with a type of psychotherapy called Exposure Therapy is helpful to patients with anorexia nervosa. DCS is approved by the FDA as an antibiotic medication, but has not been approved by the FDA for the treatment of anorexia nervosa. Past studies have found that DCS together with Exposure Therapy can help people with height phobia, social phobia, and obsessive compulsive disorder. Anorexia nervosa often includes phobia-like fears, obsessive thoughts, and compulsive rituals, so the current study aims to determine whether DCS paired with Exposure Therapy can also help people with anorexia nervosa. Anorexia nervosa is a disorder characterized by self-starvation, extreme weight loss, and difficulty maintaining a normal weight. You have been asked to participate in this study because you have been given a diagnosis of anorexia nervosa. In this study you will receive one of three therapies: Exposure Therapy with DCS, Exposure Therapy with placebo (inactive medication), or Treatment as Usual. You will participate in a total of four test meals in a laboratory setting. A total of 70 individuals with anorexia nervosa will participate in this study. Twenty individuals who have never had an eating disorder will participate in one portion of this study.
PURPOSE:To obtain an aqueous solution of a fat-soluble substance extremely stable at high temperatures in preservation for a long period and within a wide pH range by blending the fat-soluble substance with polyoxyethylene polyoxypropylene ether and polyoxyethylene hardened castor oil. CONSTITUTION:The objective aqueous solution obtained by blending a fat-soluble substance, such as vitamin E, K and derivatives thereof with 0.5-5 pts.wt. polyoxyethylene polyoxypropylene ether and further polyoxyethylene hardened castor oil in an amount of 2-20 pts.wt. based on the polyoxyethylene polyoxypropylene ether, dissolving the ingredients while heating, homogeneously stirring the mixture and adding water thereto. The aforementioned aqueous solution is useful as an injection, eye drop, drink and lotion. The fat-soluble substance can be solubilized with a smaller amount of a solubilizing agent by using the polyoxyethylene polyoxypropylene ether and polyoxyethylene hardened castor oil as the solubilizing agent.